MedTrace Logo

Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis

NCT04571151 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-11-20

No results posted yet for this study

Summary

The study seeks to show whether there is additional benefit of using Lexette and Sorilux in the beginning of the treatment, and then maintenance treatment of Sorilux alone in moderate plaque type psoriasis patients.

Conditions

Interventions

DRUG

LEXETTE 0.05% Topical Foam

Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.

DRUG

Sorilux 0.005 % Topical Foam

Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.

OTHER

Vehicle Foam

Vehicle Foam would be applied over the affected area twice daily for 6 weeks.

Sponsors & Collaborators

  • Skin Sciences, PLLC

    lead OTHER

Principal Investigators

  • Leon H Kircik · Skin Sciences, PLLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-31
Primary Completion
2021-11-30
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04571151 on ClinicalTrials.gov